New pill shows promise for Hard-to-Treat uterine cancer
NCT ID NCT07522697
First seen Apr 15, 2026 · Last updated Jun 19, 2026 · Updated 8 times
Summary
This phase 2 trial is testing a daily pill called Inavolisib in about 48 people with advanced endometrial cancer that has a specific genetic change (PIK3CA mutation). The drug targets that mutation to try to shrink tumors or stop them from growing. Researchers will measure how many patients respond to treatment and how long it takes for the cancer to progress.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Institute of Napoli, Division of Medical Oncology - Uro-Gynecology Department
Naples, 80131, Italy
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Inavolisib (a targeted cancer drug taken as a daily pill)
What this could lead to
If successful, this could provide a new treatment option for people with advanced endometrial cancer that has a specific genetic mutation (PIK3CA), potentially shrinking tumors or slowing disease progression.
What could go wrong
This is an early phase 2 trial with only 48 participants and no comparison group, so results may not be definitive. The drug may cause side effects or not work for everyone, and it is not yet known if it improves survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.